| 1.335 0.045 (3.49%) | 12-10 15:59 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.67  |
1-year : | 3.42 |
| Resists | First : | 2.28 |
Second : | 2.93 |
| Pivot price | 1.36 |
|||
| Supports | First : | 1.25 | Second : | 1.03 |
| MAs | MA(5) : | 1.34 |
MA(20) : | 1.48 |
| MA(100) : | 2.9 |
MA(250) : | 0 | |
| MACD | MACD : | -0.3 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 15.5 |
D(3) : | 12.9 |
| RSI | RSI(14): 32.3 |
|||
| 52-week | High : | 5.92 | Low : | 1.25 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ STIM ] has closed above bottom band by 40.4%. Bollinger Bands are 72.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.36 - 1.36 | 1.36 - 1.37 |
| Low: | 1.26 - 1.27 | 1.27 - 1.27 |
| Close: | 1.32 - 1.33 | 1.33 - 1.35 |
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
Thu, 20 Nov 2025
Neuronetics to Participate at the Piper Sandler 37th Annual Healthcare Conference - GlobeNewswire
Fri, 14 Nov 2025
Slammed 29% Neuronetics, Inc. (NASDAQ:STIM) Screens Well Here But There Might Be A Catch - simplywall.st
Thu, 06 Nov 2025
The Neuronetics, Inc. (NASDAQ:STIM) Third-Quarter Results Are Out And Analysts Have Published New Forecasts - simplywall.st
Tue, 04 Nov 2025
Neuronetics Inc (STIM) Q3 2025 Earnings: EPS of $(0.13) Misses E - GuruFocus
Tue, 04 Nov 2025
Neuronetics (STIM) Reports Q3 Loss, Misses Revenue Estimates - Nasdaq
Tue, 04 Nov 2025
Neuronetics Inc (STIM) Q3 2025 Earnings Call Highlights: Revenue Surges Amid Strategic Acquisitions - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 68 (M) |
| Shares Float | 39 (M) |
| Held by Insiders | 9.1 (%) |
| Held by Institutions | 61.3 (%) |
| Shares Short | 6,520 (K) |
| Shares Short P.Month | 5,810 (K) |
| EPS | -0.83 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.4 |
| Profit Margin | -34.3 % |
| Operating Margin | -19.7 % |
| Return on Assets (ttm) | -21.3 % |
| Return on Equity (ttm) | -219 % |
| Qtrly Rev. Growth | 101.3 % |
| Gross Profit (p.s.) | 0.96 |
| Sales Per Share | 1.89 |
| EBITDA (p.s.) | -0.5 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -30 (M) |
| Levered Free Cash Flow | -17 (M) |
| PE Ratio | -1.61 |
| PEG Ratio | 0 |
| Price to Book value | 3.33 |
| Price to Sales | 0.7 |
| Price to Cash Flow | -3.07 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|